{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:53:39Z","timestamp":1791104019448,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.eururo.2007.07.009","type":"journal-article","created":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T07:45:25Z","timestamp":1184744725000},"page":"1204-1212","source":"Crossref","is-referenced-by-count":206,"title":["Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder"],"prefix":"10.1016","volume":"52","author":[{"given":"Christopher","family":"Chapple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Kerrebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tubaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Theo","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2007.07.009_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.07.009_bib2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2007.07.009_bib3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.07.009_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.102.034991","article-title":"Emerging pharmacologic approaches for the treatment of lower urinary tract disorders","volume":"308","author":"Moreland","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.eururo.2007.07.009_bib5","unstructured":"Nitti V, Wiatrak M, Kreitman L, Lipsitz D. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. Paper presented at International Continence Society, Montreal, Canada, August 31\u2013September 2, 2005."},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2007.07.009_bib6","first-page":"428","article-title":"Multiple dose pharmacokinetics of fesoterodine in human subjects [abstract]","volume":"365","author":"Cawello","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.eururo.2007.07.009_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.euus.2004.09.001","article-title":"Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline","volume":"2","author":"Tubaro","year":"2004","journal-title":"EAU Update Series"},{"key":"10.1016\/j.eururo.2007.07.009_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1464-410X.2003.04468.x","article-title":"Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial","volume":"92","author":"Homma","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2007.07.009_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.07.009_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0149-2918(02)85137-2","article-title":"A multicenter, prospective, open-label study of tolterodine extended-release 4mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT)","volume":"24","author":"Siami","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2007.07.009_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1358\/dof.2004.029.07.854168","article-title":"Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update","volume":"29","author":"Cole","year":"2004","journal-title":"Drugs of the Future"},{"key":"10.1016\/j.eururo.2007.07.009_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.07.009_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.07.009_bib14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00002018-200427130-00005","article-title":"Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults","volume":"27","author":"Garely","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.eururo.2007.07.009_bib15","unstructured":"Ditropan\u00ae (oxybutynin chloride). Full prescribing information. Mountain View (CA): ALZA Corporation; 1998."},{"key":"10.1016\/j.eururo.2007.07.009_bib16","series-title":"(Tolterodine tartrate extended release capsules). Full prescribing information","author":"Detrol","year":"2003"},{"key":"10.1016\/j.eururo.2007.07.009_bib17","unstructured":"VESIcare\u00ae (Solifenacin succinate). Full prescribing information. Norman (OK): Yamanouchi Pharma America, Inc, and GlaxoSmithKline; 2004."},{"key":"10.1016\/j.eururo.2007.07.009_bib18","unstructured":"Enablex\u00ae (Darifenacin). Full prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2004."},{"key":"10.1016\/j.eururo.2007.07.009_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0024-3205(98)00585-2","article-title":"Muscarinic antagonists in development for disorders of smooth muscle function","volume":"64","author":"Wallis","year":"1999","journal-title":"Life Sci"},{"key":"10.1016\/j.eururo.2007.07.009_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.eururo.2006.05.014","article-title":"The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms","volume":"50","author":"Schagen van Leeuwen","year":"2006","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807009153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807009153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T19:52:38Z","timestamp":1546717958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283807009153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0302283807009153"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2007.07.009","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}